The RBD-ACE2 binding inhibition, anti-S-IgG levels and seroconversion rates (sVNT, S-IgG) of IBD patients and healthy controls after SARS-CoV-2 infection did not differ significantly (Table 2). The gene discussed is ACE2; the disease is inflammatory bowel disease.